Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subetta in Impaired Glucose Tolerance
NCT03725033Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in impaired glucose tolerance (IGT) comparing Subetta with Placebo (2 arms). Primary endpoint: Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test) at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
Subetta
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT03725033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725033.